Jentadueto

Jentadueto is a combination oral antidiabetic medication used in the management of Type 2 Diabetes Mellitus (T2DM)

Component Generic Names Pharmacologic Class
Linagliptin Dipeptidyl Peptidase-4 (DPP-4) inhibitor Incretin enhancer
Metformin hydrochloride Biguanide Insulin sensitizer

Mechanism of Action

1. Linagliptin (DPP-4 inhibitor)

  • Inhibits the DPP-4 enzyme, which normally degrades incretin hormones (GLP-1 and GIP).
  • Increased incretin levels → enhanced glucose-dependent insulin secretion and reduced glucagon secretion → lower fasting and postprandial glucose.
  • Has minimal risk of hypoglycemia and is weight-neutral.
  • Unlike other DPP-4 inhibitors (e.g., sitagliptin), linagliptin does not require renal dose adjustment because it’s primarily excreted via the bile and gut.

2. Metformin (Biguanide)

  • Decreases hepatic glucose production (inhibits gluconeogenesis).
  • Increases insulin sensitivity and peripheral glucose uptake.
  • Decreases intestinal glucose absorption.
  • Promotes mild weight loss and does not cause hypoglycemia (when used alone).

Indication

  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • May be used as initial therapy in patients inadequately controlled with diet/exercise alone, or as step-up therapy when monotherapy with metformin or linagliptin is insufficient.

Available Strengths (U.S. & Canada)

Linagliptin / Metformin HCl (mg) Tablet
2.5 mg / 500 mg Film-coated tablet
2.5 mg / 850 mg Film-coated tablet
2.5 mg / 1000 mg Film-coated tablet

Usual Adult Dose

  • Initial: 1 tablet twice daily with meals (based on patient’s current metformin dose).
  • Max dose: 5 mg linagliptin / 2000 mg metformin per day (i.e., 2.5/1000 mg twice daily).
  • Adjust according to tolerability and renal function.

Renal Dose Adjustment

  • Linagliptin: No adjustment needed.
  • Metformin:
    • eGFR ≥ 60 mL/min: No adjustment.
    • eGFR 45–59: Continue with caution; monitor renal function q3–6 months.
    • eGFR 30–44: Reduce dose by 50%; avoid initiation.
    • eGFR < 30: Contraindicated (risk of lactic acidosis).

Contraindications

  • eGFR < 30 mL/min/1.73 m²
  • Acute or chronic metabolic acidosis (including lactic acidosis)
  • Hypersensitivity to linagliptin, metformin, or any component of the product

Major Adverse Effects

Component Common Effects Serious / Rare Effects
Linagliptin Nasopharyngitis, cough, arthralgia Pancreatitis, hypersensitivity reactions, bullous pemphigoid
Metformin GI upset (nausea, diarrhea, abdominal discomfort), metallic taste Lactic acidosis (rare but serious, esp. in renal/hepatic impairment), vitamin B12 deficiency with long-term use

Drug Interactions

  • Linagliptin: minimal CYP interactions; may increase risk of hypoglycemia if combined with insulin or sulfonylureas.
  • Metformin: interactions with cationic drugs eliminated by renal tubular secretion (e.g., cimetidine), contrast media (risk of lactic acidosis).
  • Temporarily discontinue before iodinated contrast imaging and restart after renal function reassessment (48 hours).

Monitoring Parameters (Clinical Pharmacist Focus)

Parameter Frequency Notes
HbA1c Every 3 months Assess long-term glycemic control
Fasting & postprandial glucose Ongoing Dose titration and daily control
Renal function (eGFR) Baseline, then annually (q3–6 mo if borderline) Adjust metformin if eGFR <45
Hepatic function Periodically Metformin contraindicated in hepatic failure
Vitamin B12 Every 2–3 years Risk of deficiency with long-term metformin use
GI tolerance Ongoing Gradual dose titration reduces side effects

Clinical Pearls

  • Advantages: Convenient single tablet, complementary mechanisms, low risk of hypoglycemia, weight neutral.
  • Counseling: Take with meals to reduce GI side effects.
  • Storage: Room temperature; protect from moisture.
  • Trade Name: Jentadueto®
  • Manufacturer: Boehringer Ingelheim / Eli Lilly
Links